Analysis: Health sector, big pharma spent big on lobbying for COVID-19 funding

August 12, 2020

(PROVO, Utah -- 10 Aug. 2020) To date, Congress has authorized roughly $3 trillion in COVID-19 relief assistance -- the largest relief package in history. With more COVID relief money on the way, a new study led by two Brigham Young University business professors finds these newly available funds led to a significant surge in health sector lobbying activity, especially within the pharmaceutical industry.

The research, publishing Wednesday, Aug. 12, in the Journal of General Internal Medicine, finds the lobbying expenditures ($248.4 million) and new lobbyist registrations (357) of the health sector represented nearly a fourth of all lobbying activity, across all industries, in the first quarter of 2020.

"This is like sharks to blood, or bees to honey, if you prefer a milder metaphor," said study author Bill Tayler, an accounting professor in the BYU Marriott School of Business. "Congress is giving out a lot of money, so the lobbyists are swarming. Lobbying activity levels are typically fairly stable, so when you see jumps like this, it's a big deal."

According to the analysis, health sector lobbying spending increased more than 10% in Q1 of 2020 while non-health sector increased only 1%. Meanwhile, the number of new lobbyists registered in the health sector increased a staggering 140% while non-health sector registrations increased only 63%.

The BYU researchers, in collaboration with colleagues from Johns Hopkins University, Columbia University and the University of Cincinnati, found that across all segments of health sector lobbying, the biggest lobbying increases came from the pharmaceutical industry. Indeed, 16 of the top 30 healthcare organizations in lobbyist expenditures were pharmaceuticals.

For example, Novartis International increased their lobbying expenditures by 259% this year, AbbVie Inc. increased theirs by 155% and Biogen Inc. increased their expenditures by a whopping 344%. The organization with the highest lobbying expenditures by far was Pharmaceutical Research and Manufacturers of America (PhRMA), a non-profit trade association largely sponsored by pharmaceutical companies, spending $11.5 million in the first quarter of 2020.

"This is the largest stimulus bill in history," said study coauthor John Barrick, a fellow accounting professor at BYU and expert on lobbying policy. "It's important to follow the money. Dollars spent on lobbying influence the allocation of funds and, right or wrong, I think that's what people need to know."

The data shows Big Pharma has had a very loud voice as Congress has tried to allocate funds to small businesses, the unemployed, healthcare and more.

Overall, the top 30 healthcare organizations (16 of which were pharmaceutical organizations) spent almost $100 million on lobbying in Q1 of 2020, which represented a 55% increase in lobbying spending over Q4 of 2019. The authors said the results of the study illustrate just how much the health sector and others are willing to invest to influence Congress' appropriation and allocation of funds.

"The return on investment on a dollar of lobbying appears much higher than a dollar of R&D," said study coauthor Shivaram Rajgopal, a professor of accounting and auditing at Columbia Business School. Added senior author Ge Bai: "The health sector's investment in lobbying has apparently generated handsome returns."
Adam Olson, an assistant professor of accounting at the Carl H. Lindner College of Business at the University of Cincinnati is the first author on the paper. Olson completed his undergraduate degree in economics at BYU.

Brigham Young University

Related Healthcare Articles from Brightsurf:

How to protect healthcare workers from COVID-19
Researchers are developing simple and inexpensive tools--like a DIY ventilator--to treat patients more effectively and prevent disease transmission in hospitals.

Healthcare as a climate solution
Although the link may not be obvious, healthcare and climate change -- two issues that pose major challenges around the world -- are in fact more connected than society may realize.

Healthcare's earthquake: Lessons from COVID-19
Leaders and clinician researchers from Beth Israel Lahey Health propose using complexity science to identify strategies that healthcare organizations can use to respond better to the ongoing pandemic and to anticipate future challenges to healthcare delivery.

Poor women in Bangladesh reluctant to use healthcare
A study, published in PLOS ONE, found that the women living in Dhaka slums were reluctant to use institutionalised maternal health care for fear of having to make undocumented payments, unfamiliar institutional processes, lack of social and family support, matters of honour and shame, a culture of silence and inadequate spousal communication on health issues.

Women and men executives have differing perceptions of healthcare workplaces according to a survey report in the Journal of Healthcare Management
Healthcare organizations that can attract and retain talented women executives have the advantage over their peers, finds a special report in the September/October issue of the Journal of Healthcare Management, an official publication of the American College of Healthcare Executives (ACHE).

Greater financial integration generally not associated with better healthcare quality
New findings from a Dartmouth-led study, published in the August issue of Health Affairs, show that larger, more integrated healthcare systems do not generally deliver better quality care, and that there is significant variation in quality scores across hospitals and physician practices, regardless of whether they are independent or owned by larger systems.

Wearable sensor may help to assess stress in healthcare workers
A wearable biosensor may help monitor stress experienced by healthcare professionals, according to a study published in Physiological Reports.

Healthcare innovators focus on 'quality as a business strategy' -- update from Journal of Healthcare Quality
Despite two decades of effort -- targeting care processes, outcomes, and most recently the value of care - progress has been slow in closing the gap between quality and cost in the US healthcare system.

How runaway healthcare costs are a threat to older adults and what to do about it
Empowering Medicare to directly negotiate drug prices, accelerating the adoption of value-based care, using philanthropy as a catalyst for reform and expanding senior-specific models of care are among recommendations for reducing healthcare costs published in a new special report and supplement to the Winter 2019-20 edition of Generations, the journal of the American Society of Aging (ASA).

How can healthcare achieve real technology driven transformation?
Real transformation in healthcare through the adoption of artificial intelligence (AI), robotics, telecommunications, and other advanced technologies could provide significant improvements in healthcare quality, productivity, and access.

Read More: Healthcare News and Healthcare Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to